
Reset all filters
01 4Premarin Family
02 7Premarin family
Main Therapeutic Indication : Urology
Currency : USD
2020 Revenue in Millions : 680
2019 Revenue in Millions : 734
Growth (%) : -7
Main Therapeutic Indication : Urology
Currency : USD
2021 Revenue in Millions : 563
2020 Revenue in Millions : 680
Growth (%) : -17
Main Therapeutic Indication : Women's Health
Currency : USD
2022 Revenue in Millions : 455
2021 Revenue in Millions : 563
Growth (%) : -19
Main Therapeutic Indication : Women's Health
Currency : USD
2023 Revenue in Millions : 397
2022 Revenue in Millions : 455
Growth (%) : -13
Main Therapeutic Indication : Women?s Health
Currency : USD
2024 Revenue in Millions : 380
2023 Revenue in Millions : 397
Growth (%) : -4
Main Therapeutic Indication : Sexual Health
Currency : USD
2014 Revenue in Millions : -1.50%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Sexual Health
Currency : USD
2015 Revenue in Millions : 1,076
2014 Revenue in Millions : 1,018
Growth (%) : -5%
Main Therapeutic Indication : Sexual Health
Currency : USD
2016 Revenue in Millions : 1,017
2015 Revenue in Millions : 1,018
Growth (%) : 0
Main Therapeutic Indication : Sexual Health
Currency : USD
2017 Revenue in Millions : 977
2016 Revenue in Millions : 1,017
Growth (%) : -4
Main Therapeutic Indication : Sexual Health
Currency : USD
2018 Revenue in Millions : 832
2017 Revenue in Millions : 977
Growth (%) : -15%